Early-onset, chronic nonanterior uveitis in children increases the risk of ocular complications, with 44.3% experiencing issues like cataracts and macular edema. Persistent chronic uveitis is a ...
SEATTLE — Uveitis expert Nisha Acharya, MD, shared three clinical pearls on the condition at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting. "Chronic or recurrent uveitis ...
ANI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN, a fluocinolone acetonide intravitreal implant, allowing it to be used ...
YUTIQ addresses a significant unmet need in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The uveitis treatment market is projected to grow steadily, ...
Please provide your email address to receive an email when new articles are posted on . Clinicians should take a detailed ocular and systemic history and perform a dilated exam. Some findings require ...
Significantly fewer patients in the fluocinolone acetonide intravitreal implant group experienced recurrence of uveitis at 6 months compared with the sham group. The Food and Drug Administration (FDA) ...
Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™. Highlighting the latest ophthalmology-related news reported across MJH Life Sciences ™. Leveraging Autoantibodies ...
Yutiq is supplied as a 0.18mg single-dose, preloaded applicator with a 25-gauge needle. EyePoint announced the launch of Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results